Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stroke

Disappointing results for clazosentan in CONSCIOUS-2

Nature Reviews Neurology volume 7, pages 660–661 (2011)Cite this article

Subjects

Clazosentan—a drug previously demonstrated to reduce angiographic vasospasm in patients with aneurysmal subarachnoid hemorrhage—had no significant effect on vasospasm-related morbidity and mortality in the CONSCIOUS-2 trial. A multifactorial cause for delayed ischemic neurological deficits might partly account for these negative findings.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lovelock, C. E., Rinkel, G. J. & Rothwell, P. M. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology 74, 1494–1501 (2010).

    Article  CAS  Google Scholar 

  2. Crowley, R. W. et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 42, 919–923 (2011).

    Article  Google Scholar 

  3. Vatter, H., Konczalla, J. & Seifert, V. Endothelin related pathophysiology in cerebral vasospasm: what happens to the cerebral vessels? Acta Neurochir. Suppl. 110, 177–180 (2011).

    PubMed  Google Scholar 

  4. Macdonald, R. L. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm after subarachnoid hemorrhage. Expert Opin. Investig. Drugs 17, 1761–1767 (2008).

    Article  CAS  Google Scholar 

  5. Macdonald, R. L. et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 10, 618–625 (2011).

    Article  CAS  Google Scholar 

  6. Vergouwen, M. D., Vermeulen, M., Coert, B. A., Stroes, E. S. & Roos, Y. B. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J. Cereb. Blood Flow Metab. 28, 1761–1770 (2008).

    Article  Google Scholar 

  7. Leng, L. Z., Fink, M. E. & Iadecola, C. Spreading depolarization: a possible new culprit in the delayed cerebral ischemia of subarachnoid hemorrhage. Arch. Neurol. 68, 31–36 (2011).

    Article  Google Scholar 

  8. Ko, S. B. et al. Quantitative analysis of hemorrhage volume for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Stroke 42, 669–674 (2011).

    Article  Google Scholar 

  9. Sabri, M., Ai, J. & Macdonald, R. L. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 42, 1454–1460 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, Room 428, Neurological Institute of New York, 710 West 168th Street, New York, 10032, NY, USA

    Philip M. Meyers & E. Sander Connolly Jr

Authors
  1. Philip M. Meyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Sander Connolly Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Sander Connolly Jr.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyers, P., Connolly, E. Disappointing results for clazosentan in CONSCIOUS-2. Nat Rev Neurol 7, 660–661 (2011). https://doi.org/10.1038/nrneurol.2011.168

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.168

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing